Immunotherapy in NSCLC Patients with Brain Metastases

Immunotherapy in NSCLC Patients with Brain Metastases

Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases (BMs) during their disease, with considerable morbidity and mortality. The management of BMs in patients with NSCLC is a clinical challenge and requires a multidisciplinary approach to gain effective...

Full description

Bibliographic Details
Main Authors: Silvia Buriolla, Giacomo Pelizzari, Carla Corvaja, Martina Alberti, Giada Targato, Martina Bortolot, Sara Torresan, Francesco Cortiula, Gianpiero Fasola, Alessandro Follador
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:International Journal of Molecular Sciences
Subjects:
NSCLC
immunotherapy
brain
metastases
Online Access:https://www.mdpi.com/1422-0067/23/13/7068

Internet

https://www.mdpi.com/1422-0067/23/13/7068

Similar Items